Form 4: Teva Pharmaceutical Industries Director, Varda Shalev, Reports Acquisition of Restricted Share Units

Director Varda Shalev reports acquisition of 9,632 restricted share units in Teva Pharmaceutical Industries on June 6, 2024.

Summary

• Varda Shalev, a director of Teva Pharmaceutical Industries, filed a Form 4 on June 10, 2024, reporting a transaction.
• On June 6, 2024, Shalev acquired 9,632 restricted share units (RSUs).
• These RSUs represent a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement, as determined by the Human Resources and Compensation Committee.
• The RSUs were granted on June 6, 2024, and will vest on June 6, 2025.
• Following the reported transaction, Shalev directly owns 9,632 ordinary shares represented by American Depositary Shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to stock ownership. The acquisition of shares by a director is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of restricted share units by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of restricted share units in the future suggests an expectation of continued service and contribution from the director.

Industry Context

This filing is a routine disclosure related to executive compensation and ownership in a publicly traded company. It provides transparency to investors regarding the alignment of management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of restricted share units by a director can positively influence shareholder sentiment by aligning management's interests with those of the shareholders.

Key Dates